Henan Taloph Pharmaceutical Stock Co (SHSE:600222) EBIT: ¥132 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
58 GF Score
Price ¥7.45
GF Value ¥4.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co EBIT?

Henan Taloph Pharmaceutical Stock Co SHSE:600222 -5.93% 58 EBIT is ¥132 Mil as of Mar. 2026. GuruFocus rates SHSE:600222 with a GF Score™ of 58/100 and a GF Value™ of ¥4.91 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Henan Taloph Pharmaceutical Stock Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥16 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥132 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Henan Taloph Pharmaceutical Stock Co's annualized ROC % for the quarter that ended in Mar. 2026 was 2.65%. Henan Taloph Pharmaceutical Stock Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Henan Taloph Pharmaceutical Stock Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.64%.

Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Henan Taloph Pharmaceutical Stock Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=78.332 * ( 1 - 7.29% )/( (2595.24 + 2886.609)/ 2 )
=72.6215972/2740.9245
=2.65 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3641.528 - 778.706 - ( 323.612 - max(0, 1873.622 - 2141.204+323.612))
=2595.24

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3675.222 - 607.078 - ( 181.535 - max(0, 1736.835 - 2187.04+181.535))
=2886.609

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Henan Taloph Pharmaceutical Stock Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=65.9/( ( (487.206 + max(266.604, 0)) + (475.718 + max(606.001, 0)) )/ 2 )
=65.9/( ( 753.81 + 1081.719 )/ 2 )
=65.9/917.7645
=7.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(990.552 + 353.828 + 111.24) - (778.706 + 0 + 410.31)
=266.604

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1050.27 + 462.702 + 109.279) - (607.078 + 0 + 409.172)
=606.001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Henan Taloph Pharmaceutical Stock Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=132.416/5018.468
=2.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co EBIT Related Terms

Henan Taloph Pharmaceutical Stock Co EBIT Historical Data

* Premium members only.

The historical data trend for Henan Taloph Pharmaceutical Stock Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co EBIT Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.59 -19.87 95.68 93.90 132.94

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.00 33.89 24.78 57.28 16.48

SHSE:600222 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Henan Taloph Pharmaceutical Stock Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's EV-to-EBIT falls into.


SHSE:600222
58GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Taloph Pharmaceutical Stock Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥132 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥132 Mil mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a EBIT of ¥132 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Henan Taloph Pharmaceutical Stock Co.
Is Henan Taloph Pharmaceutical Stock Co's EBIT too high?
Henan Taloph Pharmaceutical Stock Co's current EBIT is ¥132 Mil. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's EBIT compare to ZTS and UTHR?
Henan Taloph Pharmaceutical Stock Co's EBIT of ¥132 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Henan Taloph Pharmaceutical Stock Co. Henan Taloph Pharmaceutical Stock Co's current EBIT is ¥132 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.91, compared to a current price of ¥7.45 — trading 51.7% above its estimated fair value. The current EBIT is ¥132 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current EBIT is ¥132 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥7.45 is trading 51.7% above its estimated GF Value™ of ¥4.91. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • EBIT: ¥132 Mil
  • GF Value™: ¥4.91 vs. price of ¥7.45 (51.7% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
58GF Score

Get the complete analysis for SHSE:600222

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.45
Price
¥4.91
GF Value